Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Xilio Therapeutics, Inc. (XLO)

Xilio Therapeutics re-elects four directors, approves amended 2021 stock incentive plan

Neutral Impact 2 of 5 leadership Written later

At its June 10, 2026 annual meeting, Xilio Therapeutics stockholders re-elected four Class II directors and approved an amended and restated 2021 Stock Incentive Plan. Director Daniel Curran moved from Class II to Class III so each class now has three directors, with no change to his compensation.

Key points

  • June 10, 2026: annual meeting; stockholders re-elected Akintunde Bello, Daniel Curran, Robert Ross and Yuan Xu as Class II directors
  • Daniel Curran resigned as a Class II director and was re-appointed as a Class III director, with a term ending at the 2027 annual meeting
  • Stockholders approved the amended 2021 plan with 3,424,710 votes for and 355,015 against; the plan counts prefunded warrant shares in the annual evergreen increase
  • Stockholders ratified Ernst & Young LLP as auditor for fiscal 2026 with 5,047,290 votes for and 11,876 against

The filing

CompanyXilio Therapeutics, Inc. (XLO)
Form8-K, current report
Filed with the SECJun 12, 2026, 4:05 PM ET
Accession number0001193125-26-269358

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.